AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06274021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal stimulation at 50 Hz
Description: Transcutaneous spinal stimulation (TSS) is a non-invasive neuromodulation method that uses electrical currents to stimulate sensory fibers. The procedure involves placing surface electrodes midline on the lower back (T11-12 spinal processes) and on each side of the belly button. The stimulation frequency during the intervention is 50 Hz, performed at a sub-motor threshold for 30 minutes.
Study NCT06274021 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal stimulation at 50 Hz and single dose of baclofen
Description: Transcutaneous spinal stimulation (TSS) is a non-invasive neuromodulation method that uses electrical currents to stimulate sensory fibers. The procedure involves placing surface electrodes midline on the lower back (T11-12 spinal processes) and on each side of the belly button. The stimulation frequency during the intervention is 50 Hz, performed at a sub-motor threshold for 30 minutes.~Study participants will receive a single dose of baclofen, a centrally-acting muscle relaxant belonging to the class of gamma-aminobutyric acid (GABA) analogs. Its primary mechanism involves acting on the GABA receptors in the brain and spinal cord to decrease spasticity. Participants will receive baclofen orally at a single dose of 10 mg.
Study NCT06274021 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal stimulation at 50 Hz and single dose of tizanidine
Description: Transcutaneous spinal stimulation (TSS) is a non-invasive neuromodulation method that uses electrical currents to stimulate sensory fibers. The procedure involves placing surface electrodes midline on the lower back (T11-12 spinal processes) and on each side of the belly button. The stimulation frequency during the intervention is 50 Hz, performed at a sub-motor threshold for 30 minutes.~Study participants will receive a medication called tizanidine, which is an alpha-2 adrenergic agonist. This medication works by inhibiting presynaptic motor neurons, resulting in a reduction of muscle spasticity. It is commonly used to manage spasticity caused by neurological disorders. Each participant will be given a single oral dose of 4 mg of tizanidine as part of this trial.
Study NCT06274021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham transcutaneous spinal stimulation
Description: Sham Transcutaneous spinal stimulation (TSS) involves placing two surface electrodes midline on the lower back (T11-12 spinal processes). The stimulation frequency during the intervention is 50 Hz, performed for 30 minutes.
Study NCT05132946 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve block
Description: unilateral ultrasound-guided erector spinae plane block using bupivacaine 0.25% (on the left side) with total volume 0.5 ml/kg and a maximum dose of 2 mg/kg of bupivacaine in erector spinae plane block group patients
Study NCT04853290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided peripheral venipuncture
Description: Ultrasound-guided peripheral venipuncture performed by a proficient vascular access registered nurse. The procedure will be performed according to the standard operational protocol for ultrasound guided peripheral venipuncture instituted at the hospital where the study will be conducted. Site Rite 8 or Site Rite 5 ultrasound machines (Bard Access Systems, Inc., USA) will be used on the procedures.
Study NCT04853290 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional peripheral venipuncture
Description: Conventional peripheral venipuncture performed by the registered nurse at the clinical inpatient unit. The procedure will be performed according to the standard operational protocol for peripheral venipuncture protocol instituted in the hospital where the study will be conducted
Study NCT05159193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel (T)
Description: docetaxel (T) 75 mg/m\^2, i.v., d1, q3w
Study NCT05159193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin (Cb)
Description: carboplatin (Cb) AUC 6, i.v., d1, q3w
Study NCT05265676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin Sodium (Venus Remedies Limited)
Description: The test drug is enoxaparin sodium pre-filled syringe 40 mg/0.4mL of Venus Remedies Limited, India
Study NCT05159193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab (H)
Description: trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1, q3w
Study NCT05159193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pertuzumab (P)
Description: pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1, q3w
Study NCT06012669 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dose Human Lactoferrin
Description: Dietary Supplement and Food Ingredient
Study NCT05265676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin Sodium (Sanofi)
Description: The reference drug is enoxaparin sodium pre-filled syringe 40 mg/0.4mL of Sanofi, Germany
Study NCT06012669 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low dose Human Lactoferrin
Description: Dietary Supplement and Food Ingredient
Study NCT06012669 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Bovine Lactoferrin
Description: Dietary Supplement and Food Ingredient
Study NCT04837560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ElastiMed's SACS 2.0
Description: A wearable medical device that improve circulation using smart materials
Study NCT05110066 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary endarterectomy
Description: Surgical pulmonary endarterectomy is done by a thoracic surgical procedure by removing chronic thrombotic material by intimal dissection with patient on cardiopulmonary bypass.
Study NCT05110066 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon pulmonary angioplasty
Description: Percutaneous balloon pulmonary angioplasty is performed using standard percutaneous technique to break the fibrotic clots in the pulmonary arteries using percutaneous transluminal angioplasty balloons.
Study NCT05639764 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculus Quest 2
Description: A specific immersive virtual reality software designed to address chronic shoulder pain on the Oculus Quest 2 device.
Study NCT05639764 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oculus Quest 2
Description: a VRi placebo intervention with the game Tsuro, which consists of a puzzle-based strategy game where the patient will have to solve a maze by placing pieces.
Study NCT05888116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hidrante HA
Description: Apply the 5 ml single dose three times a week, every other day, preferably at night before going to bed for 4 weeks.
Study NCT05888116 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cumlaude Hidrante Interno®
Description: Apply the 5 ml single dose three times a week, every other day, preferably at night before going to bed for 4 weeks.
Study NCT05417321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0036
Description: Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0036 via intravenous infusion. HB0036 IV every 3 weeks (q3w).
Study NCT05707130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gaze stabilization exercises
Description: patients will perform gaze stabilization exercise, Static neck exercise, and Habituation exercise. Neck isometric exercises like isometric flexion, extension, lateral bending will be performed.
Study NCT05707130 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neck isometrics
Description: Patients in Conventional group will get neck isometric exercises like isometric flexion, extension, lateral bending.
Study NCT05701735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CECIL Patient Decision Aid
Description: The CECIL patient decision aid explicitly identifies the disease, the index decision, and the treatment options, describes the positive and negative features and consequences of each option, and guides the patient in examining personal values and preferences, to arrive at a quality and realistic decision.~The decision aid will be developed and validated according to the guidelines and standards published by the International Patient Decision Aids Standards (IPDAS) Collaboration.
Study NCT05993143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Round and white tablets
Study NCT05993143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Round and white tablets
Study NCT04934072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FKS518
Description: Participants will receive FKS518 via subcutaneous injection, every 26 weeks.
Study NCT04934072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-licensed Prolia
Description: Participants will receive US-licensed Prolia via subcutaneous injection, every 26 weeks.
Study NCT06150443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Description: Two osteopathic primary care physicians will performing osteopathic manipulative techniques with a minimum of three direct techniques focused on carpal tunnel. These techniques will include the interosseous membrane technique, the flexor retinaculum soft tissue technique, and the radiocarpal somatic dysfunction technique. They will also evaluate and treat the cervical spine, with particular attention to the C5-7 levels, all the way to the wrist and hand as they see fit based on the findings of their osteopathic structural exam.
Study NCT06150443 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic manipulative treatment (OMT)
Description: Two osteopathic primary care physicians will performing osteopathic manipulative techniques with a minimum of three direct techniques focused on carpal tunnel. These techniques will include the interosseous membrane technique, the flexor retinaculum soft tissue technique, and the radiocarpal somatic dysfunction technique. They will also evaluate and treat the cervical spine, with particular attention to the C5-7 levels, all the way to the wrist and hand as they see fit based on the findings of their osteopathic structural exam.
Study NCT06150443 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Conservative therapy will be defined as including the use of splints, NSAIDs, opioids, and therapeutic injection of the carpal tunnel with steroids. Physical therapy will be excluded from the conservative therapy regimen.
Study NCT06244927 — intervention group
Intervention type: PROCEDURE
Intervention: Replantation surgery
Description: Surgery
Study NCT05498298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biopotentials measurement with gtec device
Description: A measurement of 40 minutes is performed with the gtec g.Hlamp to collect biopotential signals. 32 electrodes are attached to the body (abdomen, thorax and back).
Study NCT05124938 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory investigations for control: a-Complete blood count. b-Liver function test. c-kidney function test. d-thyroid-stimulating hormone,T3 and T4. e-Assessment of levels of CA19-9.
Description: a-Complete blood count. b-Liver function test. c-kidney function test d-thyroid-stimulating hormone,T3 and T4. e-Assessment of levels of CA19-9.
Study NCT05557812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-eugenol based ZOE base material with Ferric Sulfate in primary molar pulpotomies
Description: non-eugenol based ZOE base material placed over ferric sulphate, during vital pulp therapy (pulpotomy) in primary molars
Study NCT05557812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eugenol based zinc oxide and Ferric Sulfate
Description: eugenol based zinc oxide base material placed over Ferric Sulfate medicament, during vital pulp therapy (pulpotomy) in primary molars
Study NCT06570824 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active TMS
Description: Transcranial magnetic stimulation using MagVenture XP Orange Stimulator using active side of MagVenture Cool-B70 coil
Study NCT06570824 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham TMS
Description: Sham transcranial magnetic stimulation using MagVenture XP Orange Stimulator, flipping the active side of the MagVenture Cool-B70 coil
Study NCT04854798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Splenic Ultrasound
Description: Daily ultrasound application to the spleen of approximately 18 minutes for up to 7 days, in addition to standard clinical care
Study NCT05270135 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ASAP
Description: ASAP is an intervention geared toward increasing non-stigmatized syringe sales to people who inject drugs to prevent bloodborne illnesses.
Study NCT05728541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYH2043
Description: Patients will receive SYH2043 once everyday on day 1-21 of each 28-day cycle
Study NCT00115960 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-1 gag DNA
Description: DNA vaccine containing the HIV gene gag
Study NCT00115960 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-15 DNA adjuvant
Description: Cytokine injection
Study NCT00115960 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-12 DNA adjuvant
Description: Cytokine injection
Study NCT05672030 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: No intervention.
Study NCT05587153 — intervention group
Intervention type: OTHER
Intervention: perfusion index in all parturient recruited for the study
Description: Using perfusion index and positional hemodynamic changes for the prediction of postspinal hypotension in all parturient recruited for the study
Study NCT05000801 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccine
Description: Autologous/or HLA-matched donors' DCs loaded with WT1/TERT/survivin
Study NCT05412329 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC012F injection
Description: GC012F injection is a autologous dual CAR-T targeted BCMA and CD19. A single infusion of CART cells will be administered intravenously.
Study NCT06447792 — intervention group
Intervention type: OTHER
Intervention: Loading protocol
Description: The prosthetic restoration and functional loading of the dental implant.
Study NCT04723030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carleilizumab+apathy mesylate+radiotherapy+paclitaxel (albumin-bound)
Description: Carrilizumab ：200mg,q2w; Apatinib :250mg,d1; which is taken continuously for 5 days and stopped for 2 days, and stopped for 2 weeks after radiotherapy.~Taxol :125mg/m2,q2w; Gemcitabine :1000mg/m2, q2w; cisplatin :25mg/m2, q2w; Radiotherapy:30Gy, divided into five times and completed within one week.
Study NCT05182112 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole liver irradiation (WLI)
Description: Whole liver irradiation (WLI) to a total dose 1800cGy in 10 fractions will be given over 2 weeks with simultaneously integrated boost (SIB) to deliver focal doses of 3600cGy (dose level 1) and 4800cGy (dose level 2) to select gross lesions. SIBl dose assignment will be according to the dose escalation scheme, with all patients in dose level 1 receiving boost of 3600cGy to select lesions and those in dose level 2 receiving boosts of 4800cGy to select lesions. At least one lesion will be selected for dose escalation.
Study NCT05182112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Cisplatin
Description: Patients will start cisplatin 10 mg/m2 and gemcitabine 600 mg/m2 intravenously q2 weeks for 1 cycle while undergoing simulation and radiation treatment planning procedures. After completion of CRT, adjuvant cisplatin 25 mg/m2 and gemcitabine 600 mg/m2 q2 weeks will be continued until progression or unacceptable toxicity.
Study NCT05970172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Oral
Study NCT05122819 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mandibular Molar Extraction Under Local Anesthesia
Description: Local Anaesthetic to be used: 2% Lidocaine in 1.8 ml cartridge (regularly used for dental anaesthesia regardless of the technique).~Pain on injection and local anaesthesia success will be checked by using numeric pain rating scale (NPRS).
Study NCT05122819 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mandibular Molar Extraction Under Local Anesthesia
Description: Local Anaesthetic to be used: 2% Lidocaine in 1.8 ml cartridge (regularly used for dental anaesthesia regardless of the technique).~Pain on injection and local anaesthesia success will be checked by using numeric pain rating scale (NPRS).
Study NCT05587790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Management Intervention
Description: Participants attend virtual dietary education sessions and over time create a diet plan that satisfies their individual needs. Participants aim to lose 1-2 pounds weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and anthropometric measures of waist and hip circumference, and body composition.
Study NCT05514392 — intervention group
Intervention type: DEVICE
Intervention: HP Cosmos Torqoalizer
Description: Participants will sign a consent form approved by the ethics committee. Height, weight, thigh length, leg length, foot length and kinematic foot length will be recorded before data collection. Ergometer positions will be adjusted according to participant preference. Participants will be invited to the Health Sciences University Physiotherapy and Rehabilitation Hall once. Before starting the exercise of the participants, muscle activity, balance assessment, leg fatigue will be evaluated. Participants will be made an exercise protocol. At the end of the exercise, necessary evaluations will be made again, and then the person will rest for 1 hour. After 1 hour, the exercise groups will change; Persons receiving single foot bicycle ergometer training will receive double foot bicycle ergometer training, and the group receiving double foot bicycle ergometer training will receive single foot bicycle ergometer training. Necessary evaluations will be repeated at the end of the training.
Study NCT04625153 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC18 160mg
Description: RC18 160mg is injected subcutaneously once a week for 48 times.
Study NCT04625153 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC18 240mg
Description: RC18 240mg is injected subcutaneously once a week for 48 times.
Study NCT06011226 — intervention group
Intervention type: OTHER
Intervention: focus groups
Description: A dozen patients with Chiari malformation and syringomyelia (n = 4) or isolated Chiari malformation (n = 4) or isolated syringomyelia (n = 4) will be brought together in at least two focus groups. Each focus group will include 5 to 8 patients and will last approximately 1 to 2 hours. The focus groups will be recorded (audio only, no personal data will be collected during these sessions) and will be conducted in the presence of a neurosurgeon and a psychologist, who will moderate the session.
Study NCT06011226 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: developed questionnaire will be proposed to the patients in phase 2 and 3
Study NCT05751408 — intervention group
Intervention type: PROCEDURE
Intervention: gait analysis using 3D (Vicon) and IMU (Movella)
Description: Subjects are measured using Vicon 3D analysis, combined with IMU-sensors
Study NCT06647160 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue star MAX-5 spectacle lens
Description: The children in the experimental group will wear Blue star MAX-5 spectacle lens and receive follow-up examinations every half year.
Study NCT06647160 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single-vision spectacle lens
Description: The children in the single-vision lenses group will wear single-vision spectacle lens and receive follow-up examinations every half year.
Study NCT05211947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: BI 425809
Study NCT05408169 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Suggested deadline for return of screening test
Description: A screening invitation letter modified to state, highlighted in yellow: Please return your kit within \[X\] weeks (by \[DD.MM.YYYY\]) or as soon as possible.
Study NCT05805501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobemstomig
Description: Participants will receive IV tobemstomig Q3W.
Study NCT05805501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Participants will receive IV tiragolumab Q3W.
Study NCT05805501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Participants will receive IV pembrolizumab Q3W.
Study NCT05805501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Participants will receive axitinib PO BID.
Study NCT05805501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Axitinib
Description: Participants will receive axitinib PO BID.
Study NCT05523895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: Pimavanserin
Study NCT05523895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pimavanserin matching placebo
Study NCT05440786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Orally
Study NCT05440786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV